# OnCo record rezvilutamide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/rezvilutamide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "rezvilutamide" ;
  schema:name "Rezvilutamide"@en ;
  schema:description "Rezvilutamide is Hengrui's androgen receptor blocker, approved in China in 2022 for high-volume metastatic hormone-sensitive prostate cancer on the CHART trial, where it improved survival over bicalutamide."@en ;
  schema:url <https://onco.cc/drugs/rezvilutamide/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=SHR3680> ;
  onco:status "approved" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral androgen receptor antagonist" ;
  onco:approval "CN 2022: High-volume metastatic hormone-sensitive prostate cancer with androgen deprivation therapy" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:trials <https://onco.cc/trials/nct07241416/>, <https://onco.cc/trials/nct07230106/>, <https://onco.cc/trials/nct07407283/> .